Emerging studies suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to offer a significant development for weight treatment. Preliminary patient trials have indicated substantial decreases in body fat , potentially surpassing existing body composition medications . Despite this, m… Read More